These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4392 related articles for article (PubMed ID: 17520845)

  • 41. Cetuximab-induced acneiform eruption and the response to isotretinoin.
    Vezzoli P; Marzano AV; Onida F; Alessi E; Galassi B; Tomirotti M; Berti E
    Acta Derm Venereol; 2008; 88(1):84-6. PubMed ID: 18176767
    [No Abstract]   [Full Text] [Related]  

  • 42. [Cutaneous reactions due to the use of epidermal growth factor receptor inhibitors: two case reports].
    Rodarte CM; Abdallah OA; Barbosa NF; Koch Lde O; Resende UM
    An Bras Dermatol; 2009; 84(6):667-70. PubMed ID: 20191181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Skin Manifestations of Targeted Antineoplastic Therapy.
    Sanmartín O
    Curr Probl Dermatol; 2018; 53():93-104. PubMed ID: 29131041
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
    Deslandres M; Sibaud V; Chevreau C; Delord JP
    Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
    Agirgol S; Çaytemel C; Pilanci KN
    Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rosaceiform eruption induced by cetuximab.
    Fernández-Torres R; Martínez Gomez W; Cuevas Santos J; Paradela S; Fonseca Capdevila E
    Eur J Dermatol; 2010; 20(3):392-3. PubMed ID: 20172848
    [No Abstract]   [Full Text] [Related]  

  • 47. [Acneiform eruptions induced by cetuximab].
    Walon L; Gilbeau C; Lachapelle JM
    Ann Dermatol Venereol; 2003 Apr; 130(4):443-6. PubMed ID: 12843857
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Common side effects of anti-EGFR therapy: acneform rash.
    Sipples R
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adverse cutaneous effects of neratinib.
    Hamid RN; Ahn CS; Huang WW
    J Dermatolog Treat; 2019 Aug; 30(5):487-488. PubMed ID: 30321080
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Erlotinib-induced pustular eruption.
    Cusano F; Ferrara G; Barletta E; Ingordo V
    G Ital Dermatol Venereol; 2009 Feb; 144(1):93-6. PubMed ID: 19218915
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Masago K; Irie K; Fujita S; Imamichi F; Okada Y; Katakami N; Fukushima S; Yatabe Y
    Oncology; 2018; 95(4):251-256. PubMed ID: 29902802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.
    Fabbrocini G; Panariello L; Cacciapuoti S; Bianca D; Ayala F
    Dermatitis; 2012; 23(5):237-8. PubMed ID: 23010833
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Severe EGFR inhibitor-induced acneiform eruption responding to dapsone.
    Beshay A; Petersen M; Rhoads JLW
    Dermatol Online J; 2021 Jul; 27(7):. PubMed ID: 34391331
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition.
    Wollenberg A; Moosmann N; Klein E; Katzer K
    Exp Dermatol; 2008 Sep; 17(9):790-2. PubMed ID: 18503553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
    Yamaki M; Sugiura K; Muro Y; Shimoyama Y; Tomita Y
    Exp Dermatol; 2010 Aug; 19(8):730-5. PubMed ID: 20590818
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
    Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Adverse cutaneous reactions to erlotinib].
    Pitarch G; Garde J; Torrijos A; Juárez A; Febrer MI; Camps C
    Actas Dermosifiliogr; 2008; 99(1):54-60. PubMed ID: 18206087
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cutaneous lesions due to inhibition of epidermal growth factor receptor].
    Bierhoff E; Seifert HW; Dirschka T
    Pathologe; 2006 Feb; 27(1):53-6. PubMed ID: 16362261
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
    Treudler R; Zouboulis CC
    Dermatology; 2005; 211(4):375-6. PubMed ID: 16286753
    [No Abstract]   [Full Text] [Related]  

  • 60. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
    Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 220.